Literature DB >> 19334090

Intrauterine exposure to mycophenolate mofetil and multiple congenital anomalies in a newborn: possible teratogenic effect.

Paige Jackson1, Lisa Paquette, Valerie Watiker, Linda Randolph, Rangasamy Ramanathan, Istvan Seri.   

Abstract

There is very little data linking the use of immunomodulating agents following solid organ transplantation in pregnant women with specific congenital anomalies in the offspring. Here we report on a late preterm infant with multiple, nonsyndromic, congenital anomalies including microtia/anotia, cleft lip and palate, micrognathia, ocular hypertelorism, microphthalmia and cataracts, complex congenital heart disease, rib anomalies, and intestinal malrotation. The similarity of the complex anomalies in our case to other reported cases suggests that the abnormalities are likely due to mycophenolate mofetil alone or in combination with other immunosuppressive medications taken by the mother during pregnancy. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19334090     DOI: 10.1002/ajmg.a.32715

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  4 in total

1.  What Is the Teratogenic Risk of Mycophenolate?

Authors:  Ranjit I Kylat
Journal:  J Pediatr Genet       Date:  2017-01-02

Review 2.  Leveraging the electronic health record to improve quality and safety in rheumatology.

Authors:  Gabriela Schmajuk; Jinoos Yazdany
Journal:  Rheumatol Int       Date:  2017-08-29       Impact factor: 2.631

Review 3.  Update on the Teratogenicity of Maternal Mycophenolate Mofetil.

Authors:  Lisa A Coscia; Dawn P Armenti; Ryan W King; Nicole M Sifontis; Serban Constantinescu; Michael J Moritz
Journal:  J Pediatr Genet       Date:  2015-06

Review 4.  Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty.

Authors:  Minawaer Abudou; Taixiang Wu; Jennifer R Evans; Xueyi Chen
Journal:  Cochrane Database Syst Rev       Date:  2015-08-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.